Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
Fungoides Foiler
San Francisco - Cytokine therapies that enhance the T-helper 1 (TH1) response may be the key to effective treatment of mycosis fungoides, according to David P. Fivenson, M.D. The treatments, still in the investigative stage, have potential advantages over existing treatments because their selectivity of action also reduces the risk of nonselectivity-related toxicity, he said, noting that mycosis fungoides is now typically termed cutaneous T-cell lymphoma.
Related Videos
Related Content
